Psychotic |
Psychotic |
Psychotic |
Psychotic |
Psychotic |
Psychotic |
|
Double-blind, placebo, controlled study |
Subjects with schizophrenia
N = 28 |
CBD or placebo 300 mg, 600 mg/day |
No improvements on
selective attention were observed with either dose of CBD |
(Hallak et
al., 2010) |
|
Randomized, placebo-controlled, parallel group, fixed-dose study |
Subjects with chronic schizophrenia N = 41 |
CBD or placebo 600 mg/day
in addition to regular anti-psychotic treatment |
Patient augmented with
CBD showed no improvement in positive, negative and cognitive symptoms
of schizophrenia |
(Boggs et al., 2018) |
|
Double-blind, randomized, parallel-group, controlled study |
Subjects
with schizophrenia and schizophreniform psychosis N = 42 |
CBD 800
mg/day or 800 mg Amisulpride/day |
CBD was as effective as the
amisulpride in treating the symptoms of psychosis. CBD had no effect on
negative symptoms |
(F. M. Leweke et al., 2012) |
|
Randomized, double-blind, placebo-controlled parallel group study |
Subjects with schizophrenia N = 88 |
CBD or placebo 1000 mg/day in
addition to regular anti-psychotic treatment, administered orally for 6
weeks. |
Patients augmented with CBD showed improvement in positive and
no improvements in negative and cognitive symptoms of schizophrenia |
(Philip McGuire et al., 2018) |
|
Explorative, double-blind, active-controlled, randomized,
parallel-groups trial |
Subjects with schizophrenia or schizophreniform
psychosis N = 42 |
CBD 800 mg/day |
CBD improves neurocognitive
functioning with comparable efficacy in younger and acutely ill
schizophrenia patients |
(F. Markus Leweke et al., 2021) |
Anxiety |
Anxiety |
Anxiety |
Anxiety |
Anxiety |
Anxiety |
|
Randomized, double-blind, placebo controlled, cross-over study |
Subjects with SAD N = 10 |
CBD or placebo 400 mg |
Decreases in state
anxiety in the CBD group |
(Crippa et al., 2011) |
|
Double-blind, placebo-controlled study |
Healthy volunteers N = 10 |
CBD 300 mg or placebo |
CBD decreases anxiety after SPS test |
(A. W.
Zuardi et al., 1993) |
|
Randomized, double-blind, placebo-controlled trial |
Never-treated
patients with SAD N = 24, Health control N = 12 |
CBD 600 mg or placebo |
CBD reduces anxiety in SPS test |
(Bergamaschi et al.,
2011) |
|
Randomized, double-blind, placebo-controlled trial |
Healthy subjects
N = 60 |
CBD (100, 300 and 900 mg) |
Anxiety was reduced with CBD 300
mg, but not with CBD 100 and 900 mg, in the post-speech phase |
(Antonio
W. Zuardi et al., 2017) |
|
Randomized, double-blind, placebo controlled |
Healthy subjects N = 57 |
CBD (150, 300 and 600 mg) |
Pretreatment with 300 mg of CBD
significantly reduced anxiety during the speech |
(I. M. Linares et al.,
2019) |
|
A large Retrospective case series |
Primary concerns of anxiety (n =
47) or poor sleep (n = 25), total 72 |
CBD 25-75 mg/day |
Symptoms of
anxiety decreased |
(S. Shannon et al., 2019) |
Epilepsy/ seizures |
Epilepsy/ seizures |
Epilepsy/ seizures |
Epilepsy/
seizures |
Epilepsy/ seizures |
Epilepsy/ seizures |
|
Open-label interventional trial |
Subjects with severe intractable,
childhood-onset treatment-resistant epilepsy N = 214 |
CBD from 2 to 50
mg/kg/day |
CBD might reduce seizure frequency and might have an
adequate safety profile in children and young adults with highly
treatment-resistant epilepsy |
(Devinsky et al., 2016) |
|
Randomized, double-blind, placebo-controlled study |
Subjects with the
Lennox-Gastaut syndrome N = 225 |
CBD from 10 mg to 20 mg/kg/day |
CBD
resulted in reductions in frequency of drop seizures |
(Devinsky et al.,
2018) |
|
Double-blind, placebo-controlled trial
|
Subjects with Dravet syndrome and medication resistant seizures
N = 120
|
CBD up to 20 mg/kg/day
|
CBD reduced convulsive-seizure frequency
|
(Devinsky et al., 2017)
|
|
Randomized, placebo-controlled trial
|
Subjects with drug resistant seizures in tuberous sclerosis complex N =
225
|
CBD 25 mg/kg/day or
50 mg/kg/day
|
CBD significantly reduced TSC-associated seizures.
|
(Thiele et al., 2021)
|
|
Open-label, multiple-ascending dose, phase I/II study |
Subjects with
treatment-resistant epilepsy N = 61 |
CBD from 5 mg/kg to 20 mg/kg |
The
pharmacokinetics (PK) results were obtained. |
(Wheless et al.,
2019) |
Sleep/Insomnia |
Sleep/Insomnia |
Sleep/Insomnia |
Sleep/Insomnia |
Sleep/Insomnia |
Sleep/Insomnia |
|
A large Retrospective case series |
Primary concerns of anxiety (n =
47) or poor sleep (n = 25), total 72 |
CBD 25-75 mg/day |
Sleep scores
improved with the first month in 66.7% patients |
(S. Shannon et al.,
2019) |
|
Case report |
A ten-year-old girl with PTSD |
CBD 25 mg |
Steady
improvement in the quality and quantity of sleep |
(Scott Shannon &
Opila-Lehman, 2016) |
|
Double-blind, placebo-controlled, crossover study. |
Healthy subjects
N = 27 |
CBD 300 mg |
CBD does not seem to interfere with the sleep
cycle of healthy volunteers. |
(I. M. P. Linares et al.,
2018) |
Blood pressure/vasorelaxant |
Blood pressure/vasorelaxant |
Blood
pressure/vasorelaxant |
Blood pressure/vasorelaxant |
Blood
pressure/vasorelaxant |
Blood pressure/vasorelaxant |
|
Randomized crossover study |
Healthy subjects N = 9 |
CBD 600 mg |
CBD
reduces resting BP and the BP increase to stress in humans |
(Jadoon et
al., 2017) |
Diabetes |
Diabetes |
Diabetes |
Diabetes |
Diabetes |
Diabetes |
|
Randomized, double-blind, placebo-controlled, parallel group pilot
study |
Subjects with non-insulin-treated type 2 diabetes N = 62 |
CBD
100 mg twice daily |
CBD decreased resistin and increased
glucose-dependent insulinotropic peptide |
(Jadoon et al.,
2016) |
Pain relieves |
Pain relieves |
Pain relieves |
Pain relieves |
Pain
relieves |
Pain relieves |
|
Randomized, double-blind, placebo-controlled, crossover study |
Subjects with chronic, stable pain, poorly responsive to other
modalities of control N = 34 |
Sublingual spray with2.5 mg of THC, 2.5
mg CBD, or 2.5 mg THC + 2.5 mg CBD or matching placebo. |
Extracts with
THC proved most effective in symptom control |
(Notcutt et al.,
2004) |
|
Prospective, single-arm cohort study
|
Subjects between 30 to 65 years old with chronic pain who have been on
opioids for at least 1 year. N = 131
|
CBD-rich soft gels, 15.7 mg CBD each.
Two gels daily
|
CBD could significantly reduce opioid use and improve chronic pain and
sleep quality of patients
|
(Capano et al., 2020)
|
|
Multicenter, double-blind, randomized, placebo-controlled,
parallel-group trial |
Patinets with cancer pain experienced inadequate
analgesia despite chronic opioid dosing N = 177 |
22-32 mg/day THC and
20-30 mg/day CBD. |
CBD combine with THC showed a statistically
significantly reduction of pain NRS score |
(J. R. Johnson et al.,
2010) |
Cancer |
Cancer |
Cancer |
Cancer |
Cancer |
Cancer |
|
Report of objective clinical responses
|
119 cancer patients
|
CBD 5 mg to 15 mg/day
|
Clinical responses were seen in 92% of
the 119 cases
|
(Kenyon et al., 2018)
|
|
Pilot, randomized, double-blind, placebo-controlled phase II trial |
Subjects suffering from CINV N= 16 |
CBD 2.5 mg and THC 2.7 mg or
placebo |
A higher proportion of patients in the cannabis group
experienced a complete response |
(Duran et al., 2010) |
|
Randomized, placebo-controlled, phase 2 crossover trial |
Subjects
experienced CINV N = 78 |
CBD 2.5 mg and THC 2.5 mg or placebo |
THC:CBD
was active and tolerable in preventing CINV |
(Grimison et al.,
2020) |